I feel like I'm having to be Debbie Downer these d
Post# of 148160
We wont be receiving approval for all three at the same time. Assuming EUA for Severe Critical, the FDA will want us to enroll and complete a Phase 3 for Mild to Moderate, as well as for Longhaulers.
The good news is that the Longhauler trial will enroll quickly. The bad news is that it will take3-4 months to complete the trial (56 days) and submit the data to the FDA. (30-60 days)
M2M I believe would enroll fairly quickly (not as quickly), but should have a shorter follow up period.
This puts us into late Summer for phase 2 Long haulers and Phase 3 M2M.
It is possible that the FDA would allow Phase 2 data in conjunction with our CD12 data, but I dont think we should expect it. If they do allow, then M2M could be sooner than Long Haulers.